| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Roberts Center,*
Haldeman Laboratory, and Civin
Laboratory for Alzheimer's Research, Sun Health Research Institute,
Sun City, Arizona; Phenogenex,
La Jolla,
California; and Elan Pharmaceuticals,
South
San Francisco, California
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
HPC patients may be of great importance in unraveling the relative contributions and sequencing of different postmortem pathological features in AD neurodegeneration and dementia. In some cases, for example, they appear to be very early AD patients just at the margins of expression of overt clinical disease.2 We have also found that HPC patients show little or no evidence of neocortical or limbic synapse loss,5 underscoring the critical relationship of neuritic degeneration to dementia. Similarly, by seeking other AD pathophysiological processes that are not extant or not yet fully extant in HPC patients, insight into their significance for the clinical expression of AD may be gained.
Finally, the inclusion of HPC patients in AD studies may offer advantages for correlational statistics because these patients often provide an intermediate subset between ND and AD groups. In scatter plots depicting plaque counts versus dementia scores, for example, the data for ND and AD patients tend to cluster at extremes (by definition, ND patients have few plaques and low dementia scores and AD patients have many plaques and high dementia scores).6 Under these circumstances, correlational statistics essentially draw a straight line connecting the two clusters of data as if there were a continuum of points between them, leading to the potentially spurious inference that the more plaques patients have the more demented they will become.7 In fact, if one looks at the data for either group alone, the correlation may not be significant at all. For this reason, the ability of HPC patients to provide a more continuous spectrum of data between ND and AD patients lends increased substance to correlational inferences about those groups. Similarly, the demonstration that a significant correlation across several experimental groups continues to hold when only one group or another is examined also strengthens any within-subjects inferences that might be drawn from the data.
In the present research, we quantified amyloid ß peptide (Aß) concentrations, plaque type, apolipoprotein E (ApoE) allele frequency, cerebrovascular amyloid angiopathy, and paired helical filament formation in entorhinal cortex and superior frontal gyrus of ND, HPC, and AD patients. In contrast to previous qualitative observations wherein an absence of cored Aß deposits was suggested to discriminate HPC from AD patients,3,8 we found the type and number of Aß deposits to be similar in these groups. Rather, of the many variables studied, soluble Aß concentrations best distinguished HPC from AD patients. Soluble Aß40, in particular, was a very robust predictor of synapse loss, giving significant inverse correlations over all patients and within the AD group alone.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
From among 124 routine brain autopsies of ND patients without prior medical history of dementia, eight were obtained that appeared to exhibit sufficient neocortex Aß plaques and entorhinal cortex neurofibrillary tangles to otherwise qualify for the diagnosis of AD.9 These HPC patients were contrasted with eight randomly selected ND patients who had limited AD pathology and no prior medical history of dementia and eight randomly selected AD patients who had previously received a clinical diagnosis of probable AD that was confirmed neuropathologically at autopsy. Post hoc evaluation of the samples by a neuropathologist (T. Beach) using CERAD pathological criteria9 and Braak staging10 confirmed the initial assignment of patients to groups with the possible exception of one ND patient who might well have qualified for the HPC group and one HPC patient who could equally have been assigned to the ND group. Since 1) the evaluations were post hoc, 2) the primary intent of including an HPC group was to provide a more continuous range of pathology than afforded by ND and AD patients only, and 3) the statistical assessments were not materially affected by reassigning the patients, the original assignments were maintained. The ND, HPC, and AD patients evaluated here represent a second sample from our autopsy population and differ from those we previously tested for inflammatory correlates of dementia.5 Absence of material symptoms of dementia in HPC and ND patients was confirmed by reference to medical records and interviews with relatives, attending physicians, and nurses. Nonetheless, in the absence of more definitive premortem cognitive status data, the present research focuses on a correlate of dementia that is quantifiable postmortem, synapse loss,11,12 and not on dementia itself.
Brain Samples and Processing
Brains were removed at autopsy, weighed, and immersed in ice-cold 0.1 mol/L phosphate buffer (pH 7.4). They were then sectioned coronally at 1-cm intervals, and blocks of the entorhinal cortex (including the transentorhinal area) at the level of the anterior hippocampus and superior frontal gyrus at the level of the genu of the corpus callosum were dissected. These samples were post-fixed for 24 to 36 hours in ice-cold 4% buffered paraformaldehyde (pH 7.4), cut at 40 µm on a freezing microtome or paraffin embedded and cut at 6 µm on a rotary microtome, and subjected to histochemical and immunohistochemical procedures. Ventricular cerebrospinal fluid (CSF) samples and contralateral entorhinal cortex and superior frontal gyrus samples were snap frozen and stored at -80°C until assay by ELISA and other methods.
Soluble and Insoluble Aß40 and Aß42 Europium Immunoassay (EuIA)
As previously described,13 soluble and insoluble Aß40 and Aß42 were measured using EuIA methods, with rabbit polyclonal antisera R163 and R165 (P. Metha, New York Institute for Mental Disabilities, Staten Island, NY) as capture antibodies for Aß40 and Aß42, respectively, and Europium-labeled mouse monoclonal antibody 4G8 (Senetec & Mease, Maryland, MO) as the detection antibody. Data for total soluble Aß (Aß40 plus Aß42), total insoluble Aß (Aß40 plus Aß42), and Aß40 and Aß42 alone were evaluated. We note that, while correctly distinguishing the Aß40 from the Aß42 carboxy terminus of the peptides, our EuIA assay does not discriminate full-length Aß from Aß fragments. Such a discrimination could be an important target for future research, as Aß17–42, for example, has been reported to be the major constituent of the diffuse plaque.14 The soluble and insoluble Aß fractions were prepared by finely mincing 200 mg of unfixed entorhinal cortex or superior frontal gyrus from each patient, followed by homogenization in a glass Ten Broeck tissue grinder in the presence of 4 ml of 20 mmol/L Tris/HCl buffer (pH 7.4) containing 3 mmol/L EDTA, 500 µg/L leupeptin, 700 µg/L pepstatin, 350 mg/L phenylmethylsulfonyl fluoride, 100 mg/L 1,10-phenanthroline, and 100 mg/L benzamidine. The brain homogenates were spun at 220,000 x g in polyallomer tubes in a Sorval AH-650 rotor for 1 hour at 4°C. For the estimation of soluble Aß, an aliquot of 100 µl of supernatant was assayed by EuIA, as described above. For insoluble Aß quantitation, the pellet was dissolved in 5 ml of 98% glass-distilled formic acid and centrifuged at 220,000 x g for 30 minutes at 4°C. An aliquot of 50 µl was diluted 10X with 0.25 mol/L Tris/HCl (pH 7.4) plus 30% acetonitrile, then pH adjusted to 7.4 with 10 N NaOH using a microelectrode. After further dilution (5X) with 20 mmol/L Tris/HCl buffer plus 0.05% Tween-20, an aliquot of 100 µl was submitted for EuIA. Because the factors that determine Aß solubility in tissue are incompletely understood, the techniques used here necessarily establish a working definition of soluble versus insoluble Aß, as in previous studies.15 That is, those molecules that remain in the aqueous supernatant after centrifugation at 220,000 x g for 1 hour are considered as soluble Aß, and those Aß aggregates that sediment under these conditions are considered as insoluble Aß.15 By ultrafiltration and molecular sieving the soluble fraction appears to contain Aß oligomers that fall within the following size ranges: >100 kd, 30 to 100 kd, 10 to 30 kd, and <10 kd, corresponding to assemblies of >22 molecules, 7 to 22 molecules, 3 to 7 molecules, and monomers/dimers.15
CSF Aß42
CSF samples were submitted blind to Athena Diagnostics, (Worcester, MA), and levels of Aß42 were quantified as previously described.16
Immunohistochemistry and Quantification of Plaque Type, Cerebrovascular Amyloid Angiopathy, and Paired Helical Filament Formation
Routine thioflavin S histofluorescence staining to reveal Aß
deposits and neurofibrillary pathology were performed on the entorhinal
cortex and superior frontal gyrus sections. Immunohistochemistry of
Aß used mouse monoclonal antibodies 6E10 and 4G8 from Senetek & Mease
at 1:500 and 1:1000 dilutions, respectively. No material differences
were observed in staining by these antibodies, and the mean is
presented here. Aß deposits were distinguished as having a
discernible Aß-immunoreactive dense core surrounded by
Aß-immunoreactive neurites or as having diffuse Aß immunoreactivity
only.17
Paired helical filament immunohistochemistry used
anti-PHF1 antibody (gift of S. Greenberg) at a 1:500 dilution to reveal
penumbras of presumably dystrophic neurites surrounding amyloid
cores.18,19
All immunohistochemistry was performed
free-floating at the same time and in the same wells for ND, HPC, and
AD patients. As in our previous research,5
counts of the
various elements at x100 final magnification were recorded by an
observer blind to disease state. For each section, two columns of five
nonoverlapping fields stretching from the pial surface to the beginning
of the white matter were assayed. The columns were located
approximately one-third of the way in from the beginning and end of
each structure. Cerebrovascular amyloid angiopathy was quantified by a
blind observer on a scale of 0 to 3, with 0 representing no visible
vascular-associated Aß deposits and 3 representing profuse
deposition. Representative examples of thioflavin histofluorescent
plaques and tangles, Aß-immunoreactive plaques with and without
cores, paired helical filament occurrence around plaques, and
cerebrovascular amyloid angiopathy are given in Figure 1
.
|
Protein extracts from entorhinal cortex and superior frontal gyrus homogenates of ND, HPC, and AD patients were subjected to standard synaptophysin Western blot analysis and densitometry as previously described.5
Apolipoprotein E Allele Frequency
Genomic DNA was extracted20 from approximately 50-mg cerebellar samples from each patient. The purified DNA was then subjected to PCR amplification using allele-specific oligonucleotide probes that span positions 112 and 158 of the ApoE locus. Amplified ApoE PCR products were digested with restriction enzyme HhaI and electrophoresed for classification on polyacrylamide gels.21
Statistics
Parametric outcome measures that could be assayed in both entorhinal cortex and superior frontal gyrus were first evaluated by two-way repeated measures analysis of variance (ANOVA), with disease state (AD, HPC, or ND) as the first factor and brain region (entorhinal cortex or superior frontal gyrus) as the second, repeated-measures factor. For variables with overall significance, comparisons were then made between HPC and ND patients only and between HPC and AD patients only using the same two-way repeated-measures ANOVA approach. Nonparametric outcome measures (cerebrovascular amyloid angiopathy, ApoE allele frequency) were evaluated by the Kruskal-Wallis statistic (comparisons across all three groups) and the Mann-Whitney U statistic (comparisons between two groups). Correlations of a priori interest were performed using Pearson's R statistic. To ensure that significant correlations did not result simply from an anchoring of the data at one extreme by ND patients, Pearson's tests were re-run using HPC and AD patients only. The CSF Aß42 data point for one patient was excluded from analysis because it exhibited a mean value more than seven standard deviations from the other patients and more than twice that of the next highest patient. This exclusion altered the significance test by ANOVA from P < 0.10 to P < 0.01. We note that previous studies have found significant differences in CSF Aß42 when AD patients were compared with ND patients (cf Ref. 16 ).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Summary data for the experiments are given in Table 1
, including patient entry statistics.
Patients in the AD, HPC, and ND groups were well matched, with
statistically similar values for age, gender, postmortem interval, and
length of sample storage. For ND patients, the median Braak stage was
II, the median CERAD plaque score was 0, and the median CERAD
neuropathology diagnosis was "not AD". For HPC patients, the
median Braak stage was IV, the median CERAD plaque score was B, and the
median CERAD neuropathology diagnosis was "possible AD". For AD
patients, the median Braak stage was VI, the median CERAD plaque score
was C, and the median CERAD neuropathology diagnosis was "definite
AD".
|
As in our previous study,5
HPC patients had
significantly higher (>36%) synaptophysin immunoreactivity on Western
blot analysis compared with AD patients
(F1,14 = 25.8, P <
0.0003), whereas they did not differ from ND patients on this measure
(F1,14 = 1.9, P >
0.50, 7% difference; Table 1
).
Aß Deposition
The HPC group exhibited significantly greater numbers of thioflavin histofluorescent plaques (>1200%; F1,14 = 35.2, P < 0.0001), plaques without cores (>4800%; F1,14 = 38.3, P < 0.0001), or plaques with cores (>2700%; F1,14 = 26.6, P < 0.0002) compared with the ND group, whereas these measures failed to distinguish HPC from AD patients. Indeed, HPC patients had only 16% fewer thioflavin-positive plaques (F1,14 = 0.6, P > 0.50), 20% fewer plaques without cores (F1,14 = 1.4, P > 0.50), and 27% more plaques with cores (F1,14 = 0.6, P > 0.50). Across the brain regions evaluated, none of these measures was a significant within-subjects correlate of synapse loss when all of the groups or the HPC and AD groups together were considered.
Soluble and Insoluble Aß40 and Aß42 Concentrations (Figure 2)
Like the Aß plaques that can be seen under the microscope, concentrations of insoluble Aß (insoluble Aß40 plus Aß42) distinguished HPC from ND patients (F1,14 = 89.2, P < 0.0001), but failed to discriminate HPC from AD patients (F1,14 = 2.8, P > 0.30). Although in some instances there was a substantial difference among group means, insoluble Aß levels within groups were often highly variable. Mean insoluble Aß40 in AD entorhinal cortex, for example, was 53.7 ± 25.9 µg/g, some 38-fold higher than the mean for HPC entorhinal cortex. However, one-half of the AD patients actually had concentrations less than 4 µg/g, substantially overlapping the values for HPC patients and leading to a nonsignificant comparison.
|
. The association of soluble
Aß40 with synapse changes was especially striking and could be
observed in AD patients alone even in a single brain region (Figure 3D)
. Soluble Aß42, measured in ventricular CSF, also distinguished
HPC from AD (F1,14 = 9.3,
P < 0.01) but not ND
(F1,14 = 0.1, P >
0.5) patients.
|
Paired Helical Filament Formation
Paired helical filament formation in the form of
thioflavin histofluorescent neurofibrillary tangles was significantly
greater in HPC compared with ND patients (>1400%;
F1,14 = 22.8, P < 0.0003),
whereas it was significantly lower (<80%) in HPC compared with AD
patients (F1,14 = 8.7,
P < 0.02). PHF1 immunoreactivity of neurites
surrounding amyloid cores was also significantly lower (>80%) in HPC
compared with AD patients (F1,14 =
11.9, P < 0.004), but was statistically similar (0%
difference) in HPC and ND patients
(F1,14 = 0.0, P >
0.50). Both measures were significant, inverse, within-subjects
correlates of synaptic loss (for tangles, Rall
groups = -0.45, P < 0.002, and
RHPC+AD = -0.38, P <
0.04; for PHF1 immunoreactivity, Rall
groups = -0.48, P < 0.006, and
RHPC+AD = -0.44, P <
0.02; Figure 4
).
|
This variable successfully discriminated HPC from ND patients (U = 88, P < 0.02) and HPC from AD patients (U = 62, P < 0.007).
Apolipoprotein E Allele Frequency
Of the ND patients sampled, none were heterozygous or homozygous for the ApoE4 allele. Of the HPC patients sampled, three were heterozygous and none were homozygous for the E4 allele. Of the AD patients sampled, three were heterozygous and three were homozygous for the E4 allele. These distributions resulted in a significant difference in ApoE4 allele frequency among the groups (KW = 9.99, P < 0.01). We note that patients were selected for study without any prior knowledge of their ApoE types.
Although all of the measures of visible AD pathology (ie, thioflavin histofluorescent plaques, diffuse plaques, cored plaques, PHF1-immunoreactive plaques, and thioflavin histofluorescent tangles) exhibited significant effects of ApoE4 allele frequency, it is important to recognize that our study and others (cf Ref. 22 ) did not include balanced representation of ApoE4 allele frequency in all of the patient groups because the patients were randomly selected from the available autopsy pool. As a result, no patient in the ND group was either heterozygous or homozygous for the ApoE4 allele. Such a circumstance substantially violates ANOVA assumptions, and indeed, when only HPC and AD groups, both of which did contain ApoE4 patients, or AD patients alone were considered, the significant effects of ApoE4 allele frequency on plaque and tangle burden vanished. By contrast, across all subjects, HPC plus AD subjects, or AD patients alone, ApoE4 allele frequency had a significant effect on soluble Aß40 concentrations (all subjects, F2,21 = 35.12, P < 0.0001; AD and HPC, F2,13 = 17.77, P < 0.002; AD only, F2,5 = 8.05, P < 0.03), insoluble Aß40 concentrations (all subjects, F2,21 = 72.11, P < 0.0001; AD and HPC, F2,13 = 39.95, P < 0.0001; AD only, F2,5 = 12.00, P < 0.02), and soluble Aß42 concentrations (all subjects, F2,21 = 16.71, P < 0.0001; AD and HPC, F2,13 = 7.98, P < 0.006; AD only, F2,5 = 27.45, P < 0.003). Insoluble Aß42 concentrations were not significantly affected by ApoE4 allele frequency.
Although correlations of nonparametric variables with parametric variables can only be viewed as suggestive, clear within-subjects relationships of ApoE4 with increased levels of soluble Aß40 (r = 0.85, P < 0.001) and insoluble Aß40 (r = 0.53, P < 0.01) but not with levels of soluble or insoluble Aß42 were observed. In turn, both increased ApoE4 allele frequency (r = 0.59, P < 0.01) and Aß40 levels (soluble Aß40, r = 0.67, P < 0.001; insoluble Aß40, r = 0.53, P < 0.01) were highly associated with increased occurrence and severity of cerebrovascular amyloid angiopathy. ApoE4, Aß40, and cerebrovascular amyloid angiopathy were equally or even more strongly associated when AD and HPC patients alone were considered. Conversely, in both all patients and AD plus HPC patients alone, the 42-amino-acid form of Aß was not significantly correlated with ApoE frequency or cerebrovascular amyloid angiopathy.
Brain Regional Differences
Across patients, synaptophysin levels (F1,21 = 20.0, P < 0.006), tangle counts (F1,21 = 39.8, P < 0.0001), plaque counts (F1,21 = 32.1, P < 0.0005), soluble Aß40 and Aß42 (F1,21 = 5.2, P < 0.04), and insoluble Aß40 and Aß42 (F1,21 = 4.3, P < 0.05) all exhibited statistically significant differences when entorhinal cortex was compared with superior frontal gyrus, with the latter being higher on all measures except neurofibrillary tangles. Nonetheless, virtually all these measures in entorhinal cortex and superior frontal gyrus were significantly correlated across the two brain regions (synaptophysin, r = 0.45, P = 0.03; neurofibrillary tangles, r = 0.88, P < 0.001; thioflavin histofluorescent plaques, r = 0.70, P < 0.001; soluble Aß40, r = 0.89, P < 0.001; soluble Aß42, r = 0.64, P < 0.001; insoluble Aß40, r = 0.85; P < 0.001; and insoluble Aß42, r = 0.79, P < 0.001), suggesting that although the two brain regions have different predilections for AD changes, such changes occur in parallel in both structures. Similar results on brain regional changes in AD pathology were obtained in our previous study of ND, HPC, and AD patients.5
Prediction of Synaptic Change
When all of the parametric variables were placed into a step-wise linear regression model with synapse change as the outcome measure, soluble Aß40 and Aß42 concentrations were found to account for 40% of the variance, with no other significant predictors. This remained true when AD patients only were considered (R2 = 0.38, P < 0.01). Of the two, soluble Aß40 accounted for substantially more of the variance than soluble Aß42. Forcing neurofibrillary tangles and PHF1-immunoreactive plaques into the model added 2% to the variance prediction. Forcing the remaining variables into the model added only an additional 2%.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Plaque type, whether distinguished by thioflavin histofluorescence or
Aß immunohistochemistry or by the presence or absence of a distinct
core, did not discriminate HPC from AD patients, although it did
distinguish HPC from ND patients. These findings argue against the
assumption that HPC, early AD, or pathological aging patients fail to
show symptoms of dementia or evidence of neurodegeneration, despite
profuse Aß deposition, because their plaques are almost wholly of the
diffuse type.3,8,23-25
HPC and AD patients shared
statistically similar numbers of Aß deposits without a discernible
core. Likewise, the presence of plaques with a more compacted form, in
particular, an aggregated Aß core surrounded by a halo of
Aß-immunoreactive neurites,17,23
had little predictive
power. Indeed, if anything, HPC patients had more plaques with cores
than AD patients (cf superior frontal gyrus, Table 1
).
Like inflammation, which we examined in a previous study of HPC patients,5 soluble Aß (including the Aß that has reached the CSF), cerebrovascular amyloid angiopathy, and paired helical filaments in the form of neurofibrillary tangles and neuropil threads surrounding amyloid cores did distinguish HPC from AD patients. Although soluble Aß concentrations predicted synapse changes in the patients better than any of the other parametric variables studied, we would be remiss in failing to point out the striking absence of neurofibrillary tangle pathology in frontal neocortex of HPC patients. Only one of eight HPC patients exhibited any tangles in superior frontal gyrus, and these were sparse, whereas all eight HPC patients had many entorhinal cortex tangles. Nearly identical results were obtained in our previous research with six other HPC patients.5
Of the different length Aß fragments, Aß40, whether in soluble or insoluble form, was a particularly strong correlate of synapse changes and readily discriminated HPC from AD patients. Aß42 was much less robust in this regard and correlated poorly with synapse loss. Taken together with the data on soluble versus insoluble Aß, our results therefore emphasize the potential importance of soluble Aß40 and the relatively weak contribution of insoluble Aß42 to AD pathophysiology. Although insoluble Aß42 may be an essential element in neuropil Aß deposition and a necessary participant in other neurodegenerative mechanisms,13,23 neither it nor the other measures associated with it (eg, neuropil plaques) accounted for AD synapse loss or the absence of overt dementia in HPC patients. By contrast, our findings are consistent with previous results demonstrating an important role for the soluble forms of Aß in AD pathology15,26 and Aß toxicity.27,28 This may not be altogether surprising when one considers that soluble Aß has the potential to affect neurons and neurites over a much wider area than insoluble Aß, which is essentially pinned to fixed points in the neuropil in the form of plaques.
Both cerebrovascular amyloid angiopathy and ApoE4 allele frequency were highly correlated with Aß40 levels and with each other, whereas they were not correlated with Aß42 levels. The ANOVA results with ApoE also showed significant effects of ApoE4 on cerebrovascular amyloid and soluble amyloid, but not on diffuse plaques, neuritic plaques, or insoluble Aß42, the primary constituent of the neuritic plaque.29 These results confirm and extend those of Ishii et al,30 who found ApoE4 allele frequency to correlate with Aß40 but not Aß42 concentrations, Greenberg et al,31 who found ApoE4 allele frequency to correlate with earlier onset of hemorrhage in cerebrovascular amyloid angiopathy, and Alonzo and colleagues32 and Roher and colleagues,29 who found Aß40 levels to be much higher in cerebrovascular amyloid deposits than neuropil amyloid deposits. Conversely, as expected for the major Aß species in plaques,29 Aß42 levels were highly correlated with plaque density measurements, whereas Aß40 levels were not. Collectively, then, our data do not confirm the suggestion that ApoE4 patients experience an increased neuritic amyloid plaque burden.33 Rather, ApoE4 appears mainly to increase cerebrovascular amyloid burden, as previously reported,33 as well as soluble amyloid burden.
In conclusion, many of the controversies about Aß and its pathophysiological relevance may follow from the fact that the visible, insoluble form of the peptide has always been used in attempts to establish correlations with AD neurodegeneration and dementia.2,4,6,7,12 Our data suggest that it is not the Aß that we can see, the diffuse or classical plaque, but the soluble Aß that we cannot see that best explains Aß neurotoxicity.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Supported by NIA AGO7367 (J. Rogers), NIA AG11925 (A. Roher), the Arizona Alzheimer's Center (A. Roher, Y. Shen, and T. Beach), and the Alzheimer's Association (J. Rogers and T. Beach).
Accepted for publication May 12, 1999.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
4 allele dosage in sporadic Alzheimer's disease. Brain Res 1997, 748:250-252[Medline]
4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 1996, 27:1333-13374 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 1996, 47:190-196This article has been cited by other articles:
 |
|
 |
|
  N.-W. Hu, I. M. Smith, D. M. Walsh, and M. J. Rowan Soluble amyloid-{beta} peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo Brain, September 1, 2008; 131(9): 2414 - 2424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bacher, R. Dodel, B. Aljabari, K. Keyvani, P. Marambaud, R. Kayed, C. Glabe, N. Goertz, A. Hoppmann, N. Sachser, et al. CNI-1493 inhibits A{beta} production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease J. Exp. Med., July 7, 2008; 205(7): 1593 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Herczenik and M. F. B. G. Gebbink Molecular and cellular aspects of protein misfolding and disease FASEB J, July 1, 2008; 22(7): 2115 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Hartley, C. Zhao, A. C. Speier, G. A. Woodard, S. Li, Z. Li, and T. Walz Transglutaminase Induces Protofibril-like Amyloid {beta}-Protein Assemblies That Are Protease-resistant and Inhibit Long-term Potentiation J. Biol. Chem., June 13, 2008; 283(24): 16790 - 16800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Richard, M. Filali, P. Prefontaine, and S. Rivest Toll-Like Receptor 2 Acts as a Natural Innate Immune Receptor to Clear Amyloid {beta}1-42 and Delay the Cognitive Decline in a Mouse Model of Alzheimer's Disease J. Neurosci., May 28, 2008; 28(22): 5784 - 5793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Pattison, A. Sanbe, A. Maloyan, H. Osinska, R. Klevitsky, and J. Robbins Cardiomyocyte Expression of a Polyglutamine Preamyloid Oligomer Causes Heart Failure Circulation, May 27, 2008; 117(21): 2743 - 2751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Muhammad, I. Flores, H. Zhang, R. Yu, A. Staniszewski, E. Planel, M. Herman, L. Ho, R. Kreber, L. S. Honig, et al. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and A{beta} accumulation PNAS, May 20, 2008; 105(20): 7327 - 7332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-L. Ma, F. Yang, F. Calon, O. J. Ubeda, J. E. Hansen, R. H. Weisbart, W. Beech, S. A. Frautschy, and G. M. Cole p21-activated Kinase-aberrant Activation and Translocation in Alzheimer Disease Pathogenesis J. Biol. Chem., May 16, 2008; 283(20): 14132 - 14143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Haataja, T. Gurlo, C. J. Huang, and P. C. Butler Islet Amyloid in Type 2 Diabetes, and the Toxic Oligomer Hypothesis Endocr. Rev., May 1, 2008; 29(3): 303 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Williamson, A. Usardi, D. P. Hanger, and B. H. Anderton Membrane-bound {beta}-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism FASEB J, May 1, 2008; 22(5): 1552 - 1559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Head, V. Pop, V. Vasilevko, M. Hill, T. Saing, F. Sarsoza, M. Nistor, L.-A. Christie, S. Milton, C. Glabe, et al. A Two-Year Study with Fibrillar {beta}-Amyloid (A{beta}) Immunization in Aged Canines: Effects on Cognitive Function and Brain A{beta} J. Neurosci., April 2, 2008; 28(14): 3555 - 3566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Nimmrich, C. Grimm, A. Draguhn, S. Barghorn, A. Lehmann, H. Schoemaker, H. Hillen, G. Gross, U. Ebert, and C. Bruehl Amyloid {beta} Oligomers (A{beta}1-42 Globulomer) Suppress Spontaneous Synaptic Activity by Inhibition of P/Q-Type Calcium Currents J. Neurosci., January 23, 2008; 28(4): 788 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Moreno, W. E. Wu, T. Lee, A. Brickman, R. Mayeux, T. R. Brown, and S. A. Small Imaging the Abeta-Related Neurotoxicity of Alzheimer Disease Arch Neurol, October 1, 2007; 64(10): 1467 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. McConlogue, M. Buttini, J. P. Anderson, E. F. Brigham, K. S. Chen, S. B. Freedman, D. Games, K. Johnson-Wood, M. Lee, M. Zeller, et al. Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice J. Biol. Chem., September 7, 2007; 282(36): 26326 - 26334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Hammer, J. C. Schmidt, and M. R. Chapman The curli nucleator protein, CsgB, contains an amyloidogenic domain that directs CsgA polymerization PNAS, July 24, 2007; 104(30): 12494 - 12499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Green, H. Martinez-Coria, H. Khashwji, E. B. Hall, K. A. Yurko-Mauro, L. Ellis, and F. M. LaFerla Dietary Docosahexaenoic Acid and Docosapentaenoic Acid Ameliorate Amyloid-{beta} and Tau Pathology via a Mechanism Involving Presenilin 1 Levels J. Neurosci., April 18, 2007; 27(16): 4385 - 4395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Garzon and M. Fahnestock Oligomeric Amyloid Decreases Basal Levels of Brain-Derived Neurotrophic factor (BDNF) mRNA via Specific Downregulation of BDNF Transcripts IV and V in Differentiated Human Neuroblastoma Cells J. Neurosci., March 7, 2007; 27(10): 2628 - 2635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Lacor, M. C. Buniel, P. W. Furlow, A. Sanz Clemente, P. T. Velasco, M. Wood, K. L. Viola, and W. L. Klein A{beta} Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease J. Neurosci., January 24, 2007; 27(4): 796 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mendoza-Naranjo, C. Gonzalez-Billault, and R. B. Maccioni Abeta1-42 stimulates actin polymerization in hippocampal neurons through Rac1 and Cdc42 Rho GTPases J. Cell Sci., January 15, 2007; 120(2): 279 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oddo, V. Vasilevko, A. Caccamo, M. Kitazawa, D. H. Cribbs, and F. M. LaFerla Reduction of Soluble Abeta and Tau, but Not Soluble Abeta Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles J. Biol. Chem., December 22, 2006; 281(51): 39413 - 39423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang and J. Robbins Heart Failure and Protein Quality Control Circ. Res., December 8, 2006; 99(12): 1315 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Carrotta, M. Di Carlo, M. Manno, G. Montana, P. Picone, D. Romancino, and P. L. San Biagio Toxicity of recombinant {beta}-amyloid prefibrillar oligomers on the morphogenesis of the sea urchin Paracentrotus lividus FASEB J, September 1, 2006; 20(11): 1916 - 1917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Green, L. M. Billings, B. Roozendaal, J. L. McGaugh, and F. M. LaFerla Glucocorticoids Increase Amyloid-beta and Tau Pathology in a Mouse Model of Alzheimer's Disease. J. Neurosci., August 30, 2006; 26(35): 9047 - 9056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
